Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Alexandra Shimmings
CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.
Updated results of studies of its Lentiglobin gene therapy using bluebird's new manufacturing process presented at the EHA meeting are encouraging but the real test will be in the longevity of its effects and the strength of its surrogate marker.
Watch out GlaxoSmithKline and Teva: AstraZeneca's benralizumab has wind in its sails following a EU CHMP positive opinion for severe asthma. Approval in the US is also expected by year end.
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.
Kite Pharma may have been pipped to the post to be first with a CAR-T product at the US FDA, but it has sneaked in the first EU filing courtesy of PRIME for axicabtagene ciloleucel.
The positive top-line results for Merck & Co's cardiovascular outcomes trial for its CETP inhibitor anacetrapib may not be enough to de-risk the class, and questions remain about the level of clinical benefit and the regulatory options.